Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 6,127.67 times
- The company has reported losses. Due to this company has reported negative ROE
2
With ROE of 1.05%, it has a Very Expensive valuation with a 2.20 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
EUR 22,792 Million ()
209.00
NA
17.32%
0.37
1.51%
2.16
Revenue and Profits:
Net Sales:
4,097 Million
(Quarterly Results - Mar 2025)
Net Profit:
78 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-57.05%
0%
-57.05%
6 Months
-46.84%
0%
-46.84%
1 Year
-46.56%
0%
-46.56%
2 Years
-40.7%
0%
-40.7%
3 Years
-44.86%
0%
-44.86%
4 Years
-24.16%
0%
-24.16%
5 Years
0%
0%
0.0%
Koninklijke Philips NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
24.44%
EBIT Growth (5y)
298.98%
EBIT to Interest (avg)
1.97
Debt to EBITDA (avg)
6,127.67
Net Debt to Equity (avg)
0.55
Sales to Capital Employed (avg)
0.80
Tax Ratio
25.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.60%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
209
Industry P/E
Price to Book Value
2.20
EV to EBIT
46.98
EV to EBITDA
25.20
EV to Capital Employed
1.73
EV to Sales
1.65
PEG Ratio
1.64
Dividend Yield
17.27%
ROCE (Latest)
3.69%
ROE (Latest)
1.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY
Mar'25
Mar'24
Change(%)
Net Sales
4,097.00
4,138.00
-0.99%
Operating Profit (PBDIT) excl Other Income
487.00
0.00
Interest
82.00
0.00
Exceptional Items
-67.00
0.00
Consolidate Net Profit
78.00
-998.00
107.82%
Operating Profit Margin (Excl OI)
51.50%
0.00%
5.15%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2025 is -0.99% vs -0.70% in Mar 2024
Consolidated Net Profit
YoY Growth in quarter ended Mar 2025 is 107.82% vs -50.08% in Mar 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
18,021.00
18,169.00
-0.81%
Operating Profit (PBDIT) excl Other Income
2,397.00
2,082.00
15.13%
Interest
288.00
277.00
3.97%
Exceptional Items
-349.00
-429.00
18.65%
Consolidate Net Profit
-841.00
-454.00
-85.24%
Operating Profit Margin (Excl OI)
68.50%
43.60%
2.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -0.81% vs 1.92% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -85.24% vs 71.94% in Dec 2023
About Koninklijke Philips NV 
Koninklijke Philips NV
Pharmaceuticals & Biotechnology
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Company Coordinates 
Company Details
Breitner Center, Amstelplein 2 , AMSTERDAM None : 1096 BC
Registrar Details






